405 related articles for article (PubMed ID: 15870084)
1. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.
Folprecht G; Grothey A; Alberts S; Raab HR; Köhne CH
Ann Oncol; 2005 Aug; 16(8):1311-9. PubMed ID: 15870084
[TBL] [Abstract][Full Text] [Related]
2. OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.
Alberts S; Poston G
Colorectal Dis; 2003 Nov; 5 Suppl 3():20-8. PubMed ID: 23573557
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant and adjuvant therapy in relation to surgery for colorectal liver metastases.
Brouquet A; Nordlinger B
Scand J Gastroenterol; 2012 Mar; 47(3):286-95. PubMed ID: 22182353
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
[TBL] [Abstract][Full Text] [Related]
6. [Specific treatment situations in metastatic colorectal cancer].
Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.
Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E
Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585
[TBL] [Abstract][Full Text] [Related]
8. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
9. Advances in neoadjuvant therapy for colorectal cancer with liver metastases.
Pozzo C; Barone C; Kemeny NE
Cancer Treat Rev; 2008 Jun; 34(4):293-301. PubMed ID: 18291590
[TBL] [Abstract][Full Text] [Related]
10. Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?
Reddy SK; Tsung A; Marsh JW; Geller DA
J Surg Oncol; 2012 Jan; 105(1):55-9. PubMed ID: 21842519
[TBL] [Abstract][Full Text] [Related]
11. [Effect of neoadjuvant chemotherapy on the results of resection of colorectal liver metastases].
Ivorra P; Sabater L; Calvete J; Camps B; Cervantes A; Bosch A; Plazzotta C; Cassinello N; Arlandis P; Lledó S
Cir Esp; 2007 Sep; 82(3):166-71. PubMed ID: 17916288
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy in the management of colorectal metastases: A review of the literature.
Ong SY
Ann Acad Med Singap; 2003 Mar; 32(2):205-11. PubMed ID: 12772524
[TBL] [Abstract][Full Text] [Related]
13. [Colorectal cancer liver metastases -- neoadjuvant concepts for preoperative down-sizing].
Golling M; Gog C; Woeste G; Zapletal C; Wullstein C; Bechstein WO
Zentralbl Chir; 2006 Apr; 131(2):140-7. PubMed ID: 16612781
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
[TBL] [Abstract][Full Text] [Related]
15. [Induction chemotherapy and surgery of colorectal liver metastases].
Adam R; Vibert E; Pitombo M
Bull Cancer; 2006 Feb; 93 Suppl 1():S45-9. PubMed ID: 16483945
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.
Lam VW; Spiro C; Laurence JM; Johnston E; Hollands MJ; Pleass HC; Richardson AJ
Ann Surg Oncol; 2012 Apr; 19(4):1292-301. PubMed ID: 21922338
[TBL] [Abstract][Full Text] [Related]
17. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer.
Jones RP; Hamann S; Malik HZ; Fenwick SW; Poston GJ; Folprecht G
Eur J Cancer; 2014 Jun; 50(9):1590-601. PubMed ID: 24661798
[TBL] [Abstract][Full Text] [Related]
18. Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases.
Galizia G; De Vita F; Lieto E; Zamboli A; Morgillo F; Castellano P; Mabilia A; Auricchio A; Renda A; Ciardiello F; Orditura M
Oncol Rep; 2013 Dec; 30(6):2992-8. PubMed ID: 24126855
[TBL] [Abstract][Full Text] [Related]
19. High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
Phelip JM; Mineur L; De la Fouchardière C; Chatelut E; Quesada JL; Roblin X; Pezet D; Mendoza C; Buc E; Rivoire M
Ann Surg Oncol; 2016 Jul; 23(7):2161-6. PubMed ID: 26739304
[TBL] [Abstract][Full Text] [Related]
20. Resectable colorectal liver metastases: optimal sequencing of chemotherapy.
Chua TC; Morris DL
J Gastrointest Cancer; 2012 Sep; 43(3):496-8. PubMed ID: 21365476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
